Fig. 3: Validation of the binding site.

a Structural fragments of SL5 and their binding affinities to C30. b SL5M mutants and their binding affinities to C30. Mutated nucleotides are colored purple.

a Structural fragments of SL5 and their binding affinities to C30. b SL5M mutants and their binding affinities to C30. Mutated nucleotides are colored purple.